Dexcom posted first-quarter 2026 results ahead of Wall Street expectations, with revenue up 15% to $1.19 billion and adjusted EPS of $0.56. The company raised its operating and EBITDA margin outlooks ...
Add Yahoo as a preferred source to see more of our stories on Google. The Dexcom G7 Continuous Glucose Monitoring (CGM) System, shown here with an iPhone and an Apple Watch. (Courtesy of Dexcom) This ...
DexCom boosted its 2026 non-GAAP operating margin guidance to 23%-23.5% after reporting strong Q1 revenue growth and product momentum. Management credited expanded coverage for type 2 non-insulin ...
Medical device maker Dexcom on Thursday reiterated its full-year revenue forecast after beating Wall Street estimates for ...
Dexcom G7 CGMs contain a complex electronic assembly within a wearable package that stands up to the rigors of everyday ...
DexCom (NASDAQ: DXCM) held its first-quarter earnings conference call on Thursday. Below is the complete transcript from the ...
New Ontario Drug Benefit (ODB) coverage means eligible Ontarians who take insulin can now benefit from using Dexcom G7 to simplify management of their diabetes. Ontario residents eligible for ODB and ...
SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (DXCM) (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results